Fresenius Medical Care (FMS) Tops Q1 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Fresenius Renal Therapies Announces the Introduction of Next Generation Sentinel Technology to Support Fluid Management Challenges in the End Stage Renal Disease Community
May 2, 2016 9:51 AM EDTWALTHAM, Mass.--(BUSINESS WIRE)-- Fresenius Renal Therapies, a division of Fresenius Medical Care North America (FMCNA), the leading provider of products and services for the chronic kidney disease patient, announced today the introduction of its latest technological enhancement in the Crit-Line® technology product line, the CLiC device.
The CLiC device non-invasively measures hematocrit, oxygen saturation and percent change in intravascular blood volume during a patients hemodialysis (HD) treatment. As an integrated feature in the 2008T hemodialysis machine, the organizations flagship HD delivery system, the healthcare professional has immediate, real-time access to a patients hematocrit, percent... More
